What is the Material Transfer Agreements (MTA) Policy?
The plasmids provided in the general stock of the Viral Vector Core are not patented, are made freely available to investigators and do not require an MTA. In cases where an investigator provides a unique plasmid to the core for their own project, the Viral Vector Core will not distribute that material freely without permission from the investigator. If an investigator wishes to distribute their own proprietary plasmid, the MTA is the responsibility of the individual investigators and not of the Viral Vector Core.
